An Open-label, Drug Interaction Study to Evaluate Safety, Pharmacokinetic, and Pharmacodynamic Effect of Oral Administration of AV-101 Alone and in Combination With Probenecid in Healthy Subjects
Latest Information Update: 14 Feb 2023
At a glance
- Drugs AV 101 (Primary) ; Probenecid (Primary)
- Indications Major depressive disorder; Psychiatric disorders; Suicidal ideation
- Focus Pharmacokinetics
- Sponsors VistaGen Therapeutics
- 07 Feb 2023 According to a VistaGen Therapeutics media release, company expects to complete the study in the first half of 2023.
- 10 Nov 2021 According to a VistaGen Therapeutics media release, the company expect to initiate this trial in the current quarter.
- 29 Jun 2021 According to a VistaGen Therapeutics media release, the company expect to initiate this trial in second half of 2021.